BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, November 3, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» Satellos reveals drug target, lead candidate in Duchenne program
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Satellos reveals drug target, lead candidate in Duchenne program
Nov. 15, 2023
No Comments
Satellos Bioscience Inc. has disclosed further information on its lead drug program in Duchenne muscular dystrophy.
BioWorld Science
Musculoskeletal
Neurology/psychiatric
Small molecule
